SCHEMBL4125825

SCHEMBL4125825

COc1ccc([C@H](C[N+](=O)[O-])C(C(C)=O)C(C)=O)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
CYP2C19 P33261 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
LMNA P02545 3/20 0.46
ADRA1A P35348 2/20 0.40
ADRA2A P08913 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TP53 P04637 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MITF O75030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126682 0.84 ALDH1A1 (0.49) ALDH1A1CYP2C19HTTLMNAL3MBTL1
SCHEMBL16684455 0.80 ALDH1A1 (0.53) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL4126054 0.80 ALDH1A1 (0.53) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL4120406 0.77 ALDH1A1 (0.45) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL18609621 0.76 ALDH1A1 (0.56) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL29434364 0.76 ALDH1A1 (0.56) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL16785382 0.76 ALDH1A1 (0.56) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL18609424 0.75 ALDH1A1 (0.55) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL18117728 0.75 ALDH1A1 (0.55) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL18609628 0.75 ALDH1A1 (0.55) ALDH1A1CYP2C19SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084641-B2 Organocataslysts and methods of use in chemical synthesis STC.UNM (US) 2011-12-27 US disclosed
US-8084641-B2 Organocataslysts and methods of use in chemical synthesis STC.UNM (US) 2011-12-27 US disclosed
US-20090088588-A1 Organocatalysts and methods of use in chemical synthesis REGENTS OF THE UNIVERSITY OF NEW MEXICO 2009-04-02 US disclosed
US-20090088588-A1 Organocatalysts and methods of use in chemical synthesis REGENTS OF THE UNIVERSITY OF NEW MEXICO 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088588-A1 Organocatalysts and methods of use in chemical synthesis ICMT, PPOX, CYP4F3 ALDH1A1 1418/4885CYP2C19 157/4885SMN1; SMN2 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.